TLR2 and neoplasm: Directly inhibiting TLR2 with antagonists or addressing elements within the gut or tumor microbiota that trigger its activation using antimicrobial agents could potentially heighten the efficacy of certain anticancer treatments in tumors resistant to standard therapies.